🍹 We will be on vacation from June 25th to July 9th. Orders placed during this period will be shipped after July 9th.

Anaferon child 25ml drops for oral administration

  • $14.50
Sku: 79a5062d7fbc
The instruction for medical use of Anaferon medicine children's the Trade name Anaferon children's the International unlicensed name Is not present the Dosage form of the Drop for intake Structure on 1 ml of drops for intake active agents: Antibodies to scale to interferon of the person affinely cleaned 0.006 g*. excipients: maltitol – 0.06 g, glitserol – 0.03 g, potassium sorbate – 0.00165 g, citric acid anhydrous – 0.0002 g, the water purified – to 1 ml. * are entered in the form of mix of three active water cultivations of the substance divorced respectively in 10012, 10030, 10050 times. Description Colourless or almost colourless transparent liquid. Pharmacotherapeutic group Anti-infectious drugs for system use. Antiviral drugs for system use. Antiviral drugs of direct action. Antiviral drugs other. The ATH J05AX code the Pharmacological Pharmacokinetics Sensitivity properties of modern physical and chemical methods of the analysis (gas-liquid chromatography, highly effective liquid chromatography, chromaTO-mass spectrometry) does not allow to estimate the content of active agents of the drug Anaferon children's in biological liquids, bodies and fabrics that makes technically impossible studying pharmacokinetics. A pharmacodynamics Pharmacological action – immunomodulatory, antiviral. During preclinical and clinical trials the efficiency of drug concerning influenza viruses, a parainfluenza, viruses of a herpes simplex of 1 and 2 types (labial herpes, genital herpes), others herpes viruses (chicken pox, an infectious mononucleosis), enteroviruses, a virus of tick-borne encephalitis, a rotavirus, a coronavirus, a kalitsivirus, adenovirus, respiratory and syncytial (PC virus) is proved. Drug reduces concentration of a virus in the struck fabrics, influences the system of endogenous interferon and the cytokines interfaced to them, induces formation of endogenous 'early' interferon (IFN а/β) and gamma interferon (IFN γ). Stimulates the humoral and cellular immune response. Raises products of antibodies (including secretory IgA), activates functions of T-effectors, T-helperov (Tkh), normalizes their ratio. Raises a functional reserve of Tkh and other cells participating in the immune response. Is the inductor of the mixed Txl and the Tkh2-immune response: increases production of Txl cytokines (IFN γ, SILT-2) and Tkh2 (IL-4, 10), restores (modulates) balance of Tkh1/Tkh2. Increases functional activity of phagocytes and natural cells killers (EK of cells). Has anti-mutagen properties. Indications as a part of complex therapy of acute respiratory upper respiratory tract infections at children aged from 1 month up to 3 years inclusive. A route of administration and doses On 10 drops on reception (drops dose in a spoon). In the first day of treatment: the first 2 hours on 10 drops each 30 minutes, then, in the remained time, 3 more times through equal intervals. From 2nd to the 5th day: on 10 drops 3 times a day. The drug is taken out of meal. In the first day of treatment the first five administrations of drug should be carried out in an interval between feedings or in 15 minutes prior to feeding of the child or intake of liquid. Side effect reactions of the increased individual sensitivity to drug components Are possible. The contraindication - the increased individual sensitivity to drug components, - children's age up to 1 month, - to persons with hereditary intolerance of fructose Medicinal interactions of Cases of incompatibility with other medicines is not registered so far. The special instructions Safety of Use of Anaferon children's at pregnant women and in the period of a lactation it was not studied. Influence of medicine for medical use on ability to run vehicles, Anaferon mechanisms children's does not influence ability to run vehicles and other potentially dangerous mechanisms. Overdose of Cases of overdose it is not revealed so far. A release form On 25 ml in the bottles from the painted glass (type III on hydrolytic stability) corked by covers with control of the first opening with a dropper. Each bottle together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard. Storage conditions At a temperature not above 25 °C. After opening to store a bottle at a temperature not above 25 °C within 35 days. Not to freeze! To store out of children's reach. A period of storage 3 years not to apply after an expiration date Prescription status Without prescription the Producer/packer of LLC NPF MATERIA MEDIKA HOLDING, Russia, 127473, Moscow, 3rd Samotechny Lane, 9. Ph./fax: +7 (495) 684-43-33. Address of the production site of medicine Russia, 454139, Chelyabinsk, Buguruslanskaya St., 54. Holder of the registration certificate of LLC NPF MATERIA MEDIKA HOLDING, Russia. The name, the address and a contact information (phone, the fax, e-mail) of the organization accepting in the territory of the Republic of Kazakhstan claims on quality of medicines from consumers and responsible for post-registration observation of safety of medicine Representative office of LLC NPF MATERIA MEDIKA HOLDING in RKg. Almaty, Seyfullin St. 498. Ph./fax: 2734713 E-mail: kz@dep.materiamedica.ru
Write a review
Related Products
Irbit (Russia)
Rimantadine-STI 50 mg (20 tablets)
Kyivmedpreparat (Ukraine)
Gerpevir 2.5g of 5% ointment
Hemofarm (Russia)
Kagocel 12 mg (10 tablets)
Sintez (Russia)
Acyclovir-Akos 200 mg (20 tablets)
Boiron (France)
Otsillokoktsinum 1g (6 granules)
Nobel AFF (Kazakhstan)
Ulkaril 200 mg (25 tablets)
NizhPharm (Russia)
Lavomax 6's 125 mg coated tablets
Glaxo Wellcome S.A. (Spain)
Valtrex 500 mg (10 tablets)